E. Of 13 patients with myalgia, most (12/13) experienced mild events and most (12/13) resolved sponataneously. No renal toxicity was observed after 24 weeks of tenofovir plus telbivudine. Mean GFR at week 52 was significantly higher than baseline in both the monotherapy and intensification groups. These findings are consistent with both 2-year clinical data from a study of telbivudine versus lamivudine in decompensated HBV disease [26]. Furthermore, retrospective analyses of seven studies (2500 patients) in both compensated and decompensated disease showed consistent GFR improvements on telbivudine treatment for up to 6 years compared with GFR declines on lamivudine therapy. Improvement was greatest in patients more than 50 years old and those with abnormal baseline GFR; and was not associated with baseline ascites, virologic response or reduction in Child-Pugh score [27]. GFR improvement on telbivudine stands in contrast to the declines over time observed in studies of tenofovir [28] and entecavir [29]. Interestingly, GFR modeling data from Mauss et al. predict a year-on-year GFR reduction ofapproximately 2 mL/min in untreated HBV monoinfection which is halved, but not abolished, by monotherapy with lamivudine, adefovir, entecavir or tenofovir [30]. Telbivudine was not studied in the Mauss model, and more research is needed to confirm and provide a mechanism for the apparent dissimilarity of telbivudine to the other nucleosides with respect to GFR preservation. The Roadmap algorithm does not consider baseline HBV DNA in treatment decisions [16]. However, in this study, high baseline DNA was predictive of detectable Week 24 viremia requiring intensification. Almost three-quarters of patients who received tenofovir had baseline HBV DNA 9 log10 copies/mL. In future, baseline viremia may need to be considered in any treatment algorithm where decisions are made on the presence of detectable viremia early on therapy. In conclusion, telbivudine with conditional tenofovir intensification according to the Roadmap algorithm was well tolerated and, over 52 weeks, resulted in very high rates of undetectable HBV DNA, ALT normalization, and HBeAg/HBsAg clearance and seroconversion in nucleoside-naive HBeAg+ patients with chronic HBV infection, along with an improvement in GFR. The Roadmap appears to be a highly effective approach to HBV treatment and 104-week data from this study are awaited.Supporting InformationTable S1 List of ethics committees/institutional review boards.(PDF)Checklist S1 CONSORT checklist.(DOCX)Protocol S1 Study protocol.(PDF)Telbivudine 6 Conditional Tenofovir: 52-Week DataAuthor ContributionsCritical manuscript review and amendment: TP PK TT WS HLYC MGP EF SKO FB JD SZ HC RP YD AT. Conceived and designed theexperiments: TP RP YD AT. Performed the experiments: TP PK TT WS HLYC MGP EF SKO FB JD SZ HC. Analyzed the data: TP RP YD AT. Wrote the paper: YD.
Vision is initiated in the retina where light is captured by the outer Licochalcone A segment MedChemExpress AZ-876 organelle of photoreceptor cells. The outer segment is a modified primary cilium that contains large quantities of proteins involved in visual signal transduction. Similar to all cilia, the outer segment lacks the machinery required to synthesize proteins and therefore relies on the import of proteins produced in the cell body of photoreceptor cells. The importance of accurate protein targeting to the outer segment is highlighted by observations that defects in protein targeting result in retinal dege.E. Of 13 patients with myalgia, most (12/13) experienced mild events and most (12/13) resolved sponataneously. No renal toxicity was observed after 24 weeks of tenofovir plus telbivudine. Mean GFR at week 52 was significantly higher than baseline in both the monotherapy and intensification groups. These findings are consistent with both 2-year clinical data from a study of telbivudine versus lamivudine in decompensated HBV disease [26]. Furthermore, retrospective analyses of seven studies (2500 patients) in both compensated and decompensated disease showed consistent GFR improvements on telbivudine treatment for up to 6 years compared with GFR declines on lamivudine therapy. Improvement was greatest in patients more than 50 years old and those with abnormal baseline GFR; and was not associated with baseline ascites, virologic response or reduction in Child-Pugh score [27]. GFR improvement on telbivudine stands in contrast to the declines over time observed in studies of tenofovir [28] and entecavir [29]. Interestingly, GFR modeling data from Mauss et al. predict a year-on-year GFR reduction ofapproximately 2 mL/min in untreated HBV monoinfection which is halved, but not abolished, by monotherapy with lamivudine, adefovir, entecavir or tenofovir [30]. Telbivudine was not studied in the Mauss model, and more research is needed to confirm and provide a mechanism for the apparent dissimilarity of telbivudine to the other nucleosides with respect to GFR preservation. The Roadmap algorithm does not consider baseline HBV DNA in treatment decisions [16]. However, in this study, high baseline DNA was predictive of detectable Week 24 viremia requiring intensification. Almost three-quarters of patients who received tenofovir had baseline HBV DNA 9 log10 copies/mL. In future, baseline viremia may need to be considered in any treatment algorithm where decisions are made on the presence of detectable viremia early on therapy. In conclusion, telbivudine with conditional tenofovir intensification according to the Roadmap algorithm was well tolerated and, over 52 weeks, resulted in very high rates of undetectable HBV DNA, ALT normalization, and HBeAg/HBsAg clearance and seroconversion in nucleoside-naive HBeAg+ patients with chronic HBV infection, along with an improvement in GFR. The Roadmap appears to be a highly effective approach to HBV treatment and 104-week data from this study are awaited.Supporting InformationTable S1 List of ethics committees/institutional review boards.(PDF)Checklist S1 CONSORT checklist.(DOCX)Protocol S1 Study protocol.(PDF)Telbivudine 6 Conditional Tenofovir: 52-Week DataAuthor ContributionsCritical manuscript review and amendment: TP PK TT WS HLYC MGP EF SKO FB JD SZ HC RP YD AT. Conceived and designed theexperiments: TP RP YD AT. Performed the experiments: TP PK TT WS HLYC MGP EF SKO FB JD SZ HC. Analyzed the data: TP RP YD AT. Wrote the paper: YD.
Vision is initiated in the retina where light is captured by the outer segment organelle of photoreceptor cells. The outer segment is a modified primary cilium that contains large quantities of proteins involved in visual signal transduction. Similar to all cilia, the outer segment lacks the machinery required to synthesize proteins and therefore relies on the import of proteins produced in the cell body of photoreceptor cells. The importance of accurate protein targeting to the outer segment is highlighted by observations that defects in protein targeting result in retinal dege.